Boyce Sarah — SEC insider filings
SEC reporting owner CIK 1629383. 44 insider filings on record with FilingPulse; latest filed 2026-09-22.
Transaction summary — filings shown
Covers all 44 filings on record, filed 2021-02-04 to 2026-09-22. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 2 legs across 1 filing — 36,000 shares, $101,397 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 32 legs across 22 filings — 987,801 shares, $33,697,083 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 91.
- Largest priced transaction: sale of 164,233 shares @ $40.08 ($6,581,802) in Avidity Biosciences, Inc., filed 2024-06-14.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Avidity Biosciences, Inc. (RNAM) | President and CEO, Director | 28 | — | 29 legs · 977,801 sh · $33,085,746 | 62 |
| Berkeley Lights, Inc. (BLI) | Director | 2 | — | 3 legs · 10,000 sh · $611,337 | 4 |
| OmniAb, Inc. (OABI) | Director | 6 | 2 legs · 36,000 sh · $101,397 | — | 14 |
| LIGAND PHARMACEUTICALS INC (LGND) | — | 3 | — | — | 6 |
| Contineum Therapeutics, Inc. (CTNM) | Director | 3 | — | — | 3 |
| Atrium Therapeutics, Inc. (RNA) | Director | 2 | — | — | 2 |
Insider filings — Boyce Sarah
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-22 | 4 | Atrium Therapeutics, Inc. (RNA) | Tax withholding (F): 126,418 @ $8.95 | EDGAR |
| 2026-06-26 | 4 | Contineum Therapeutics, Inc. (CTNM) | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Atrium Therapeutics, Inc. (RNA) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-02-27 | 4 | Avidity Biosciences, Inc. (RNAM) | Disposition to issuer (D): 474,861 · Disposition to issuer (D): 386,015 (derivative) · Disposition to issuer (D): 300,000 (derivative) · Disposition to issuer (D): 425,000 (derivative) · Disposition to issuer (D): 400,000 (derivative) · Disposition to issuer (D): 200,000 (derivative) · +2 more | EDGAR |
| 2026-01-23 | 4 | Avidity Biosciences, Inc. (RNA) | Sale (S): 6,394 @ $72.45 · Sale (S): 7,993 @ $72.45 | EDGAR |
| 2026-01-09 | 4 | Avidity Biosciences, Inc. (RNA) | Sale (S): 8,576 @ $72.23 | EDGAR |
| 2025-12-19 | 4 | Avidity Biosciences, Inc. (RNA) | Grant/award (A): 31,000 @ $0 · Tax withholding (F): 15,742 @ $71.87 · Gift (G): 29,159 @ $0 | EDGAR |
| 2025-09-05 | 4 | Avidity Biosciences, Inc. (RNA) | Option exercise (M): 50,000 @ $1.24 · Sale (S): 50,000 @ $49.95 · Option exercise (M): 50,000 (derivative) @ $0 | EDGAR |
| 2025-08-29 | 4 | Avidity Biosciences, Inc. (RNA) | Option exercise (M): 25,000 @ $1.24 · Sale (S): 25,000 @ $49.39 · Option exercise (M): 25,000 (derivative) @ $0 | EDGAR |
| 2025-06-26 | 4 | Contineum Therapeutics, Inc. (CTNM) | Grant/award (A): 14,750 (derivative) @ $0 | EDGAR |
| 2025-03-21 | 4 | Avidity Biosciences, Inc. (RNA) | Sale (S): 31,540 @ $31.06 | EDGAR |
| 2025-01-23 | 4 | Avidity Biosciences, Inc. (RNA) | Sale (S): 4,738 @ $28.59 · Sale (S): 5,659 @ $28.59 | EDGAR |
| 2025-01-08 | 4 | Avidity Biosciences, Inc. (RNA) | Grant/award (A): 82,500 @ $0 · Grant/award (A): 165,000 (derivative) @ $0 | EDGAR |
| 2024-12-19 | 4 | Avidity Biosciences, Inc. (RNA) | Sale (S): 31,855 @ $32.66 | EDGAR |
| 2024-09-23 | 4 | Avidity Biosciences, Inc. (RNA) | Grant/award (A): 62,500 @ $0 · Sale (S): 32,880 @ $44.00 · Grant/award (A): 62,500 @ $0 | EDGAR |
| 2024-08-07 | 4 | Avidity Biosciences, Inc. (RNA) | Option exercise (M): 28,000 @ $1.24 · Sale (S): 28,000 @ $43.35 · Option exercise (M): 28,000 (derivative) @ $0 | EDGAR |
| 2024-07-11 | 4 | Avidity Biosciences, Inc. (RNA) | Option exercise (M): 28,000 @ $1.24 · Sale (S): 28,000 @ $39.93 · Option exercise (M): 28,000 (derivative) @ $0 | EDGAR |
| 2024-06-24 | 4 | Contineum Therapeutics, Inc. (CTNM) | Grant/award (A): 29,500 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | OmniAb, Inc. (OABI) | Option exercise (M): 20,000 · Option exercise (M): 20,000 (derivative) @ $0 · Grant/award (A): 20,000 (derivative) @ $0 · Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2024-06-20 | 4 | Avidity Biosciences, Inc. (RNA) | Grant/award (A): 62,500 @ $0 · Sale (S): 32,074 @ $39.13 · Grant/award (A): 62,500 @ $0 | EDGAR |
| 2024-06-14 | 4 | Avidity Biosciences, Inc. (RNA) | Option exercise (M): 100,000 @ $1.24 · Sale (S): 100,000 @ $35.73 · Option exercise (M): 164,233 @ $1.24 · Sale (S): 164,233 @ $40.08 · Option exercise (M): 35,767 @ $1.24 · Sale (S): 35,767 @ $40.08 · +3 more | EDGAR |
| 2024-06-05 | 4 | Avidity Biosciences, Inc. (RNA) | Option exercise (M): 28,000 @ $1.24 · Sale (S): 28,000 @ $27.42 · Option exercise (M): 28,000 (derivative) @ $0 | EDGAR |
| 2024-05-07 | 4 | Avidity Biosciences, Inc. (RNA) | Option exercise (M): 28,000 @ $1.24 · Sale (S): 28,000 @ $25.54 · Option exercise (M): 28,000 (derivative) @ $0 | EDGAR |
| 2024-04-23 | 4/A | OmniAb, Inc. (OABI) | Grant/award (A): 39,628 | EDGAR |
| 2024-04-03 | 4 | Avidity Biosciences, Inc. (RNA) | Option exercise (M): 28,000 @ $1.24 · Sale (S): 28,000 @ $26.25 · Option exercise (M): 28,000 (derivative) @ $0 | EDGAR |
| 2024-03-12 | 4 | Avidity Biosciences, Inc. (RNA) | Option exercise (M): 84,000 @ $1.24 · Sale (S): 84,000 @ $21.39 · Option exercise (M): 28,000 @ $1.24 · Sale (S): 28,000 @ $22.63 · Option exercise (M): 84,000 (derivative) @ $0 · Option exercise (M): 28,000 (derivative) @ $0 | EDGAR |
| 2024-03-05 | 4 | Avidity Biosciences, Inc. (RNA) | Option exercise (M): 84,000 @ $1.24 · Sale (S): 84,000 @ $20.13 · Option exercise (M): 84,000 (derivative) @ $0 | EDGAR |
| 2024-01-23 | 4 | Avidity Biosciences, Inc. (RNA) | Grant/award (A): 62,500 @ $0 · Sale (S): 5,092 @ $10.13 · Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2023-09-12 | 4 | Avidity Biosciences, Inc. (RNA) | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2023-06-27 | 4 | OmniAb, Inc. (OABI) | Grant/award (A): 20,000 (derivative) @ $0 · Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2023-02-03 | 4 | Avidity Biosciences, Inc. (RNA) | Option exercise (M): 900 @ $1.24 · Sale (S): 900 @ $24.27 · Option exercise (M): 45,879 @ $1.24 · Sale (S): 45,879 @ $24.36 · Option exercise (M): 3,221 @ $1.24 · Sale (S): 3,221 @ $24.26 · +3 more | EDGAR |
| 2023-02-01 | 4 | OmniAb, Inc. (OABI) | Grant/award (A): 8,753 @ $0 · Grant/award (A): 37,840 (derivative) @ $0 | EDGAR |
| 2023-01-24 | 4 | Avidity Biosciences, Inc. (RNA) | Grant/award (A): 50,000 @ $0 · Grant/award (A): 400,000 (derivative) @ $0 | EDGAR |
| 2022-11-14 | 4 | OmniAb, Inc. (OABI) | Purchase (P): 21,000 @ $2.74 · Purchase (P): 15,000 @ $2.92 | EDGAR |
| 2022-11-03 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Disposition to issuer (D): 1,004 · Disposition to issuer (D): 4,340 (derivative) | EDGAR |
| 2022-11-03 | 4 | OmniAb, Inc. (OABI) | Grant/award (A): 37,437 · Grant/award (A): 22,616 (derivative) · Grant/award (A): 10,565 (derivative) · Grant/award (A): 13,994 (derivative) · Grant/award (A): 37,840 (derivative) | EDGAR |
| 2022-08-26 | 4 | Avidity Biosciences, Inc. (RNA) | Option exercise (M): 35,045 @ $1.24 · Sale (S): 35,045 @ $22.80 · Option exercise (M): 14,855 @ $1.24 · Sale (S): 14,855 @ $23.07 · Option exercise (M): 35,045 (derivative) @ $0 · Option exercise (M): 14,855 (derivative) @ $0 | EDGAR |
| 2022-08-17 | 4 | Avidity Biosciences, Inc. (RNA) | Option exercise (M): 100 @ $1.24 · Sale (S): 100 @ $22.47 · Option exercise (M): 100 (derivative) @ $0 | EDGAR |
| 2022-06-13 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Grant/award (A): 1,004 @ $0 · Grant/award (A): 4,340 (derivative) @ $0 | EDGAR |
| 2022-03-15 | 4 | Avidity Biosciences, Inc. (RNA) | Grant/award (A): 425,000 (derivative) @ $0 | EDGAR |
| 2021-06-07 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Grant/award (A): 630 @ $0 · Grant/award (A): 3,269 (derivative) @ $0 | EDGAR |
| 2021-05-18 | 4 | Berkeley Lights, Inc. (BLI) | Grant/award (A): 1,400 @ $0 · Grant/award (A): 4,900 (derivative) @ $0 | EDGAR |
| 2021-03-03 | 4 | Berkeley Lights, Inc. (BLI) | Option exercise (M): 10,000 @ $8.90 · Sale (S): 3,773 @ $60.08 · Sale (S): 3,000 @ $61.13 · Sale (S): 3,227 @ $62.37 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2021-02-04 | 4 | Avidity Biosciences, Inc. (RNA) | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2021-01-29 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1629383 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs